METHODS FOR THE PREPARATION OF FISPEMIFENE FROM OSPEMIFENE

BACKGROUND Field of the Invention

[0001] This invention relates to the preparation of fispemifene using ospemifene as a starting material. Description of Related Art

[0002] The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

[0003] Ospemifene, (Z)- 2-[4-(4-Chloro-l ,2»diphenyl-but-1-enyl)phenoxy]ethanol, which is one of the main metabolites of toremifene, is known as an estrogen agonist and antagonist {Kangas, Cancer Chemother. Pharmacol. (1990) 27:8-12; WO 96/07402 and WO 97/32574). Ospemifene has relatively weak estrogenic and antiestrogenic effects in the classical hormonal tests (Kangas, 1990). It has anti- osteoporosis actions and it decreases total and LDL cholesterol levels in both experimental models and in human volunteers. It also has antitumor activity in an early stage of breast cancer development in an animal breast cancer model. Ospemifene is also the first SERM (selective estrogen receptor modulator) which has been shown to have beneficial effects in climacteric syndromes in healthy women. The use of ospemifene for the treatment of certain climacteric disorders and atrophy-related diseases or disorders in postmenopausal women is disclosed in WO 02/07718 and WO 03/103649.

[0004] WO 01/36360 describes a group of SERMs, which are tissue-specific estrogens and which can be used in women in the treatment of climacteric

symptoms, osteoporosis, Alzheimer's disease and/or cardiovascular diseases without the carcinogenic risk. Certain compounds can be given to men to protect them against osteoporosis, cardiovascular diseases and Alzheimer's disease without estrogenic adverse events (gynecomastia, decreased libido etc.). Of the compounds described in said patent publication, the compound (Z)-2-{2-[4-(4- chloro-1 ,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (also known under the generic name fispemifene) has shown a very interesting hormonal profile suggesting that it will be especially valuable for treating disorders in men. WO 2004/108645 and WO 2006/024689 suggest the use of fispemifene for treatment or prevention of age-related symptoms in men, such as lower urinary tract symptoms and diseases or disorders related to androgen deficiency in men. [0005] Known methods for the syntheses of compounds like ospemifene and fispemifene include rather many steps. WO 02/090305 describes a method for the preparation of fispemifene, where, in a first step, a triphenylbutane compound with a dihydroxysubstituted butane chain is obtained. This compound is in a second step converted to a triphenylbutene where the chain is 4-chlorosubstituted. Then the desired Z-isomer is crystallized. Finally, the protecting group is removed to release the ethanol-ethoxy chain of the molecule.

SUMMARY

[0006] Both ospemifene and fispemifene are likely to be commercialized in the near future. Thus, there is a great need for powerful methods for the preparation of these compoundsin large scale. Particularly, the object of this invention is to

provide a method for synthesis of fispemifene using ospemifene as starting material in only two steps, with no need to purify the intermediate. [0007] Thus, according to one aspect, this invention concerns a method for the preparation of a compound of formula (I)

wherein a compound of formula (II)

is alkylated with an alkylating reagent of the formula HaI-CH ₂ -COOR, wherein Hal is halogen and R is an alkyl, to give a compound of formula (III)

and the ester of formula (III) is reduced to give the compound of formula (I).

[0008] This invention is also directed to a group of novel compounds of formula (III) where R is a CrC ₄ -alkyl, preferably methyl, ethyl or t-butyl. [0009] Furthermore, this invention concerns the use of compounds of formula (III) in the manufacture of fispemifene.

DETAILED DESCRIPTION

[0010] Fispemifene is the Z-isomer of the compound of formula (I)

[0011] The starting material, compound (II), may be prepared by methods known to those of ordinary skill in the art. The alkylating agent is HaI-CH ₂ -COOR. The alkyl R in the alkylating reagent is preferably a C-ι- ₄ -alkyl, most preferably ethyl. Examples of a C-M-alkyl also include methyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and t-butyl. The step of alkylating is conducted at a temperature and for a time sufficient to achieve substantial alkylation of compound (II). The halogen (Hal) in the alkylating reagent is preferably I, Br or Cl, and most preferably Br. [0012] The reduction of the compound (III) to compound (I) is preferably carried out by lithium aluminium hydride, although other reducing agents well known to those of ordinary skill in the art may afso be used. The step of reduction is carried out at a temperature and for a time sufficient to produce substantially pure fispemifene.

[0013] The invention will be illuminated by the following non-restrictive Examples.

EXAMPLE 1

{2-[4-(4-Chloro-1 ,2-diphenyl-but-1-enyl)-phenoxy]-ethoxy}-acetic acid ethyl ester (Compound III)

[0014] 2-[4-(4-Chloro-1 ,2-diphenyl-but-1-enyl)-phenoxy]-ethanol (Compound II) (0.3 g, 0.79 mmol) was dissolved in tetrahydrofuran (5 ml) under a nitrogen atmosphere. Sodium hydride (0.058 g, 1.21 mmol) was added in THF (5 ml) to the solution and the mixture was stirred at room temperature for an hour. Then the mixture was cooled to 0 ⁰ C ₁ ethyl bromo acetate (0.4 g, 2.38 mmol) was added and the stirring was continued for 5 hours at 0-5 ⁰ C. The mixture was allowed to warm up to room temperature and stirring was continued overnight. Then the reaction is quenched with water and ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate. The organic phase was washed with water, dried with sodium sulphate and evaporated to dryness. The residue was used in the next reaction step without further purification.

[0015] ¹ H NMR (200 MHz, CDCI3): 1.25 (t, 3H, CH ₂ CH ₃ ), 2.94 (t, 2H, =CH2CH2CI), 3.44 (t, 2H, =CH2CJd2CI), 3.85-3.90 (m, 2H, OCH ₂ CH ₂ O CH ₂ CO), 4.03-4.07 (m, 2 H, OCH ₂ CH ₂ OCH ₂ CO), 4.18 (s, 2H, OCH ₂ CH ₂ OCH ₂ CO), 4.19 (q, 2H, CH ₂ CH ₃ ), 6.58 (d, 2H, aromatic proton ortho to oxygen), 6.80 (d, 2H, aromatic proton meta to oxygen), 7.1-7.43 (m, 1OH, aromatic protons).

EXAMPLE 2 2-{2-[4-(4-Chloro-1 ,2-diphenyl-buM -enyl)-phenoxy]-ethoxy}- ethanol (Compound I)

[0016] {2-[4-(4-ChJoro-1 ,2-diphenyl-but-1-enyl)-phenoxy]-ethoxy}-acetic acid ethyl ester was dissolved in tetrahydrofuran at room temperature under nitrogen

atmosphere. Lithium aluminium hydride was added to the solution in small portions until the reduction reaction was complete. The reaction was quenched with saturated aqueous ammonium chloride solution. The product was extracted into toluene, which was dried and evaporated in vacuo. The residue was purified with flash chromatography with tofuene/triethyl amine (9.5:0.5) as eluent. Yield 68 %.

[0017] ¹ H NMR (200 MHz, CDCI3): 2.92 (t, 2H, =CH2CH2CI), 3.42 (t, 2H, =CH2CH2CI), 3.59-3.64 (m, 2H ₁ OCH ₂ CH ₂ O CH ₂ CH ₂ OH), 3.69-3.80 (m, 4 H, OCH ₂ CH ₂ OCH ₂ CH ₂ OH), 3.97-4.02 (m, 2H, OCH ₂ CH ₂ OCH ₂ CH ₂ OH), 6.57 (d, 2H, aromatic proton ortho to oxygen), 6.78 (d, 2H, aromatic proton meta to oxygen), 7.1-7.43 (m, 1OH, aromatic protons).

[0018] It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for one of ordinary skill in the art that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.